The 26th JFCR－ISCC
December 7-8, 2022
Miraikan - The National Museum of Emerging Science and Innovation 7F
2-3-6, Aomi, Koto-ku, Tokyo, Japan
December 7
12:00-
Poster mounting
12:00-12:30
Committee meeting
Opening Remark
12:50-13:00
Naoya Fujita (JFCR, Tokyo)
Opening remark
Poster Flash Talks
Chairperson: Manabu Kawada (Inst. Microbial Chem., Tokyo)
13:00-13:50
Toshihiro Shibutani (Taiho Pharmaceutical Co., Ltd., Ibaraki)
TAS-115, a multi-tyrosine kinase inhibitor, modulates tumor microenvironment and potentiates the antitumor efficacy of anti-PD-1 antibody
Junjiro Yoshida (Institute of Microbial Chemistry, Tokyo)
Mitochondrial complex I inhibitors suppress tumor growth through intra- and extracellular acidification
Sosuke Nakamura (MSD K.K., Tokyo)
Zilovertamab vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma: The phase 1 dose escalation and cohort expansion WAVELINE-001 study of an anti-ROR1 antibody-drug conjugate
Shigehiro Koganemaru (National Cancer Center Hospital East, Chiba)
Relationship between the intratumor pharmacokinetics and antitumor effect of the payload Eribulin in the novel antibody-drug conjugate MORAb-202
Yuki Katayama (Kyoto Prefectural University of Medicine, Kyoto)
EGFR activation promotes adaptive resistance to lorlatinib in ALK-rearranged lung cancer cells
Shun Morino (Cancer Chemotherapy Center, JFCR, Tokyo)
Single cell lineage analysis for tracing drug-tolerant persister cells in patient-derived colorectal cancer cells
Kohei Maruyama (Cancer Chemotherapy Center, JFCR, Tokyo)
Identification of the intrinsic resistance mechanisms to KRAS inhibitors in KRAS mutated colorectal cancer.
Noritaka Tanaka (Kansai Medical University, Osaka)
The collateral effects of KRAS inhibitors on tumor microenvironment
Hiroshi Kotani (Kanazawa University, Ishikawa)
SUMOylation inhibition modulates tumor immunity and activates immune cells
Yusuke Ito (Aichi Cancer Center Research Institute, Aichi)
Optimization of CAR-T cell functions using a gene-editing approach
13:50-14:30
Poster Viewing Onsite only (No online delivery)
14:30-14:40
Break
1 New emerging molecular targets and drugs
Chairpersons: Seiji Yano (Kanazawa Univ., Ishikawa), Shingo Dan (JFCR, Tokyo)
14:40-15:05
Koji Ichikawa (Taiho Pharmaceutical Co., Ltd., Ibaraki)
TAS0612, a potent RSK/AKT/S6K inhibitor targeting cancers with PI3K and MAPK pathway aberrations
15:05-15:45
Victor Moreno (START Madrid-FJD, Madrid, Spain)
Current advances in adoptive cell therapy for solid tumors
15:45-15:55
Discussion
15:55-16:05
Break
2 Targeting KRAS/SOS
Supported by MEXT Grant-in-Aid for Scientific Research on Innovative Areas "Integrated Analysis and Regulation of Cellular Diversity (4904)"
Chairpersons: Ryan Corcoran (MGH Cancer Ctr., Boston, MA, USA),
Hiromichi Ebi (Aichi Cancer Ctr. Res. Inst., Aichi)
16:05-16:45
Ryan Corcoran (MGH Cancer Ctr., Boston, MA, USA)
Overcoming clinical resistance to KRASG12C inhibition
16:45-17:10
Yoshihisa Kobayashi (National Cancer Ctr. Res. Inst., Tokyo)
Silent mutations associated with oncogenic function of RAS
17:10-17:50
Norbert Kraut (Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria)
Targeting KRAS for cancer care
17:50-18:00
Discussion
December 8
Meet-the-Expert Session
Chairperson: Atsushi Ohtsu (National Cancer Ctr. Hospital East, Chiba)
9:00-9:40
Lillian Siu (Princess Margaret Cancer Ctr., Toronto, Canada)
Rethinking early phase clinical trials in oncology: Dose optimization
9:40-9:50
Discussion
9:50-10:00
Break
3 Targeted protein degradation and PROTACs
Chairpersons: Mikihiko Naito (Univ. Tokyo, Tokyo), Alessio Ciulli (Univ. Dundee, Dundee, UK)
10:00-10:40
Hiroshi Handa (Tokyo Medical Univ., Tokyo)
Identification of thalidomide target CRBN to the development of targeted protein degraders
10:40-11:20
Alessio Ciulli (Univ. Dundee, Dundee, UK)
How PROTAC degraders work: design principles and drug development for challenging cancer targets
11:20-12:00
Debbie Chirnomas (Arvinas, New Haven, CT, USA)
PROTAC® Protein Degraders in the Clinic
12:00-12:10
Discussion
12:10-12:30
Break
Luncheon Seminar
Chairperson: Masanobu Oshima (Kanazawa Univ., Ishikawa)
12:45-13:30
Yasuhiro Yamada (Univ. Tokyo, Tokyo)
The oncogene-dependent resistance to reprogramming unveils cancer therapeutic targets
13:30-13:40
Break
4 Next generation antibody drug therapy
Chairpersons: Shunji Takahashi (JFCR, Tokyo), Ryohei Katayama (JFCR, Tokyo)
13:40-14:05
Soichiro Nishijima (Daiichi Sankyo Co., Ltd., Tokyo)
Clinical development of DXd-ADC franchise
14:05-14:30
Yohei Otake (Eisai Co., Ltd., Tokyo)
MORAb-202 (farletuzumab ecteribulin): from preclinical research to clinical trials and translational analysis
14:30-14:55
Yosuke Togashi (Okayama Univ., Okayama)
TIGIT blockade therapies:Can they overcome resistance to PD-1 blockade therapies?
14:55-15:05
Discussion
Closing Remark
15:05-15:20
Ryan Corcoran (MGH Cancer Ctr., Boston, MA, USA)
Closing remark